When evaluating whether semaglutide might be contributing to leg cramps in an individual patient, clinicians must consider the temporal relationship between medication initiation or dose escalation and symptom onset, the presence of alternative explanations, and whether symptoms resolve with dose adjustment or discontinuation
BioMed Rep (2016) 4(1):6872
GHK-Cu FDA Approval Status 2026: Injectable Rules Overview GHK-Cu FDA Approval Status 2026: Injectable Rules
GLP-1 drugs have been approved by the FDA for diabetes and weight loss, making way for GLP-1 patches for both indications
After interest in the drugs sparked a national shortage in the U.S., the FDA approved several versions specifically for weight loss, including Zepbound and Wegovys pill form
Someone who cannot control food intake despite genuine effort might need appetite-targeting compounds first